Aging/Research reports/2026-09-30
Where does the tau go?
The decision
Yesterday identified export as a competing explanation. Today examines the measurements: We provisionally reject calculating the degraded fraction from the available signal losses. This rejects neither lysosomal processing nor TIMP2 as a candidate. It limits what these data can establish for our goal of lasting improvement in neuronal function.
One primary study joins the register: AG-D02, Shultz et al., online 18 August 2025, issue date 15 October 2025, DOI 10.1016/j.nbd.2025.107058. AG-D01, published 6 April 2026, receives a targeted follow-up on Figure 4 and measurement methods for a new, explicit question. The register now contains 24 DOI-unique studies. “New” means newly included, not published today.
Two measurement routes, different conclusions
AG-D02 · Tau-HiBiT: A luminescent reporter tracks tau after uptake and washout. RAB7A knockdown and lysosomal damage in H4 cells slow signal loss, supporting lysosomal involvement. This validation must be distinguished from the iPSC-microglia comparisons. Signals are normalized to their respective starting values. This does not yet quantify degradation through a jointly calibrated balance of cells, medium and fragments. Primary manuscript · Publication metadata and figure legends
AG-D01 · Cell signal plus medium: Figure 4 combines Tau12 immunofluorescence with a total-tau ELISA in medium. These do not directly form a common mass balance; the ELISA epitopes are proprietary. A timing discrepancy also remains: the text mentions six hours of clearance, whereas the figure shows a 24-hour chase; its 6/24-hour groups denote loading durations. We do not silently combine these as a time series. Primary study, methods 2.8/2.14 and Figure 4
Evidence and project significance are separate
- Established methodological knowledge · ⚪ Level 1: Relative signals, concentrations and total amounts are different quantities. A joint balance needs compatible calibration, volume, cell accounting and definitions of detected molecules.
- Promising indication · ⚪ Level 1: AG-D02's perturbations support lysosomal involvement in the cell model. Moderate evidence for this limited mechanism, not rejuvenation.
- External experimental results · ⚪ Level 1: The papers examine different tau species, cell models and assays. They provide complementary observations, not a joint test of the TIMP2 pathway.
- Project synthesis · 🔵 Level 2: AG-T01 still requires selective cargo degradation, preserved useful synapses, meaningful functional benefit and no harmful redistribution. The complete chain is unconfirmed; novelty remains unverified.
Why we are not calculating a degradation rate today
A normalized signal can be represented as:
r(t) = [S(t) − B] / [S(0) − B]
S denotes the measurement response and B the appropriate background. r is dimensionless; its denominator must be nonzero. 1 − r(t) initially denotes relative signal loss, not necessarily the fraction of completely destroyed tau molecules. Initial loading, reporter/epitope loss, export, cell loss and reuptake must be accounted for in the relevant measurement model. This distinction is our methodological inference, not a new measurement.
We have not verified a sufficiently matched dataset to separate these contributions quantitatively. A precise-looking fitted curve would not supply the missing information. Therefore, no effect estimate, half-life or cross-study pooling is calculated today. Instead, the audit makes a concrete decision about which analysis the current evidence permits.
Countermodels and the next executable step
The next source check will examine which tau fragments and antibody epitopes survive processing: AG-D01, sections 3.5–3.6 and method 2.13.4, plus accessible related supplements (peptide mapping: S9C/D). The output should map detected fragment, assay response, possible blind spot and relation to seeding activity. The timing discrepancy stays unresolved until a checkable source resolves it. Missing supplementary data will not be guessed.
Later external confirmation would need to assess cargo fate together with preserved synapses, neuronal function, durability and harms. Our next step is source analysis; this project performs no laboratory or clinical studies. No new efficacy claim is made for the axolotl branch today. Injury regeneration and aging reversal remain distinct questions.
Provenance, limitations and research log
AG-D02 is the peer-reviewed version of an earlier preprint; both count as one study, not replication. AG-D01 cites AG-D02. Different methods alone do not establish fully independent confirmation. A joint test of AG-T01 is absent.
Retrieved 30 September 2026. Targeted searches covered microglia/tau/degradation/export and measurement methods; AG-D02 DOI/title searches for correction/retraction found no matching notice, not a comprehensive registry audit. AG-D02: direct publisher/PMC retrieval blocked; indexed primary methods and figure legends assessed. AG-D01: publisher full text and Figure 4 assessed; supplementary access limited. No comprehensive September search or raw-data reanalysis.
This methodological deepening adds reading for AG-P17–20. No duplicate professor package or reset wish-list entry; existing assignments are preserved. No personal treatment plans or self-medication advice.
Continue exploring
